Jon Faiz Kayyem
CIK 1366268 · SVP, Research & Development · last filed 2026-06-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$39.49M
Companies
4
Total Filings
100
Lifetime Open-Market Net
$729.6K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INBX | Director | 419,360 | $93.11 | $39.05M | $1.45M | 18 | 2026-06-04 |
| BDSX | Director | 17,877 | $24.86 | $444.4K | $200.0K | 13 | 2026-01-06 |
| Inhibrx, Inc. (INBXV) Delisted | Director | 0 | — | — | $0 | 1 | 2024-05-30 |
| GenMark Diagnostics, Inc. (GNMK) Delisted | SVP, Research & Development | 286,306 | $24.04 | $6.88M | -$924.2K | 62 | 2018-02-06 |
Recent Filings · Page 5 of 10
100 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-08-04 | GenMark Diagnostics, Inc. (GNMK) Delisted | Sell (S) | −138 | -$1.4K | EDGAR |
| 2017-06-05 | GenMark Diagnostics, Inc. (GNMK) Delisted | Sell (S) | −132 | -$1.7K | EDGAR |
| 2017-05-23 | GenMark Diagnostics, Inc. (GNMK) Delisted | Sell (S) | −1,265 | -$16.3K | EDGAR |
| 2017-05-04 | GenMark Diagnostics, Inc. (GNMK) Delisted | Sell (S) | −133 | -$1.8K | EDGAR |
| 2017-03-09 | GenMark Diagnostics, Inc. (GNMK) Delisted | Sell (S) | −311 | -$3.8K | EDGAR |
| 2017-03-03 | GenMark Diagnostics, Inc. (GNMK) Delisted | Sell (S) | −131 | -$1.6K | EDGAR |
| 2017-02-24 | GenMark Diagnostics, Inc. (GNMK) Delisted | Grant (A) | +48,750 | $0 | EDGAR |
| 2017-02-21 | GenMark Diagnostics, Inc. (GNMK) Delisted | Sell (S) | −5,250 | -$52.9K | EDGAR |
| 2017-02-03 | GenMark Diagnostics, Inc. (GNMK) Delisted | Sell (S) | −131 | -$1.5K | EDGAR |
| 2017-01-20 | GenMark Diagnostics, Inc. (GNMK) Delisted | Mixed | +7,913 | -$71.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.